Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos ROVI EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Laboratorios Farmaceuticos ROVI (ROVI.MC) as of Oct 8, 2026 is 174.90 M EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 207.56 M EUR — a change of -15.73% (lower).

EBITDA

174.90 MEUR

YoY

-15.73%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Laboratorios Farmaceuticos ROVI is 2025 174.90 M EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Laboratorios Farmaceuticos ROVI was 2024 207.56 M EUR. It decreases by -15.73% lower compared to the previous year.

The Laboratorios Farmaceuticos ROVI EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
29.50 M EUR
Jan 1, 2019
61.06 M EUR
Jan 1, 2020
94.28 M EUR
Jan 1, 2021
204.72 M EUR
Jan 1, 2022
278.72 M EUR
Jan 1, 2023
244.58 M EUR
Jan 1, 2024
207.56 M EUR
Jan 1, 2025
174.90 M EUR
The Laboratorios Farmaceuticos ROVI EBITDA history
YEAREBITDAYoY
174.90 MEUR-15.73%
207.56 MEUR-15.14%
244.58 MEUR-12.25%
278.72 MEUR+36.15%
204.72 MEUR+117.15%
94.28 MEUR+54.40%
61.06 MEUR+106.97%
29.50 MEUR-3.23%
30.49 MEUR-22.47%
39.32 MEUR+23.59%
31.82 MEUR-13.01%
36.58 MEUR—
Access this data via the Eulerpool API

Laboratorios Farmaceuticos ROVI Stock analysis

What does Laboratorios Farmaceuticos ROVI do? Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Laboratorios Farmaceuticos ROVI is 174.90 M EUR in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Laboratorios Farmaceuticos ROVI changed from 207.56 M EUR to 174.90 M EUR, representing a -15.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Laboratorios Farmaceuticos ROVI since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Laboratorios Farmaceuticos ROVI historically and in real time.

Access this data via the Eulerpool API

Income Statement — Laboratorios Farmaceuticos ROVI

All Key Metrics — Laboratorios Farmaceuticos ROVI